Oral administration of baicalein (20, 40 and 80 mg/kg) improved epilepsy symptoms, attenuated microglial proliferation, decreased the expression of Insulin-like growth factor 1 receptor (IGF-1) and inhibited inflammation, as evident from the reduced expression of IL-1β, IL-6, and TNF-α in the brain of pilocarpine-induced epileptic rats [83]. This evidence concerns the gene IGF1R and epilepsy.